IRLAB Therapeutics AB (IRLABA.ST)

Nasdaq Stockholm · Financial statements, TTM figures and earnings dates

In fiscal year 2024 (ended December 31, 2024), IRLAB Therapeutics AB reported revenue of SEK 94.6M and net income of −SEK 83.1M. Annual financial statements are available for fiscal years 2020 to 2024, taken from the company's ESEF annual reports (IFRS).

Open interactive financials →

Key financials

SEK	FY2024 2024-12-31	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31	FY2020 2020-12-31
Income statement
Revenue	SEK 94.6M	SEK 5.7M	SEK 61.1M	SEK 207.8M	SEK 0
Operating income	−SEK 75.1M	−SEK 180.8M	−SEK 113.1M	SEK 52.6M	−SEK 91.5M
Net income	−SEK 83.1M	−SEK 177.8M	−SEK 113.4M	SEK 51.8M	−SEK 91.7M
Diluted EPS	−SEK 1.60	−SEK 3.43	−SEK 2.19	SEK 1.00	−SEK 1.92
Cash flow
Operating cash flow	−SEK 65.6M	−SEK 164.8M	−SEK 142.6M	SEK 128.6M	−SEK 89.2M
Capital expenditure	SEK 199.0K	SEK 293.0K	SEK 2.9M	SEK 708.0K	SEK 394.0K
Free cash flow	−SEK 65.8M	−SEK 165.1M	−SEK 145.5M	SEK 127.9M	−SEK 89.6M
Balance sheet
Cash and equivalents	SEK 66.9M	SEK 111.3M	SEK 252.8M	SEK 401.9M	SEK 277.0M
Total assets	SEK 136.2M	SEK 177.1M	SEK 323.6M	SEK 472.4M	SEK 370.1M
Total liabilities	SEK 103.6M	SEK 61.4M	SEK 32.7M	SEK 73.0M	SEK 22.2M
Total debt	SEK 53.5M	SEK 24.5M	SEK 0	–	–
Shareholders' equity	SEK 32.6M	SEK 115.8M	SEK 290.8M	SEK 399.5M	SEK 347.9M

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full IRLABA.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open IRLABA.ST financials →